Entries by Russell Radefeld

KindredBio Announces Proposed Public Offering

SAN FRANCISCO, California. (March 18, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of its common stock. The number […]

KindredBio Announces Initiation of Pivotal Clinical Study for AtoKin™ in Dogs

AtoKin™, KindredBio’s second lead product, is expected to be a major advance in the treatment of symptoms associated with atopic dermatitis. SAN FRANCISCO, California. (February 20, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated a pivotal clinical trial […]

Kindred Bio Announces Exercise of Over-Allotment Option

SAN FRANCISCO, California. (December 13, 2013) – Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the underwriters of its initial public offering exercised in full their option to purchase up to 1,125,000 additional shares of its common stock at the initial public offering price […]

KindredBio Announces Pricing of Initial Public Offering

SAN FRANCISCO, CA, Dec 11, 2013 (Marketwired via COMTEX) — Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at an initial public offering price of $7.00 per share for a total […]

KindredBio Announces Launch of Initial Public Offering

SAN FRANCISCO, California. (December 2, 2013) – Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, announced the commencement of its initial public offering of 5,750,000 shares of its common stock, at an anticipated initial public offering price between $6.00 and $8.00 per share. KindredBio also expects to […]

KindredBio Announces Initiation of Pivotal Clinical Study for CereKin™

CereKin™ (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis. SAN FRANCISCO, California – Kindred Biosciences, Inc. (KindredBio) announced today that it has initiated a pivotal clinical trial for CereKin™ (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol […]